Continuing Push to Diversify Offerings, Myriad Licenses Chronix's Early Cancer Detection Technology
May 11, 2011
Continuing Push to Diversify Offerings, Myriad Licenses Chronix's Early Cancer Detection Technology
Chronix has yet to complete validation studies for its prostate, breast, and colon early detection cancer tests, so questions remain as to when the license will begin adding to Myriad's revenues.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Posting 11 Percent Revenue Growth in FY2011, Myriad Focuses on Growing MDx Pipeline
August 10, 2011 / Pharmacogenomics Reporter - Myriad Genetics Licenses Cancer Dx Technology from Chronix
May 10, 2011 / GenomeWeb Daily News - Myriad 'Aggressively' Eyeing M&A, Companion Dx Deals, Euro Opportunities in FY 2011
August 11, 2010 / Pharmacogenomics Reporter - Reporting 27 Percent Q3 Jump, Myriad Outlines Three-Pronged Plan for Diversifying Revenue Base
May 2, 2012 / Pharmacogenomics Reporter - Myriad Outlines Marketing, Payment Plans to Counter Weak Economy, Raises Test Prices
May 5, 2010 / Pharmacogenomics Reporter